Sarepta Therapeutics has announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. The agreement will add to Sarepta’s pipeline for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs.
Company Information
Company
Sarepta Therapeutics, Inc.
Location
215 FIRST STREET
Cambridge, Maryland, United States
About
Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save
Predictive Intelligence
Strategic
ML-powered predictions for Sarepta Therapeutics, Inc.'s next move